Cargando…
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia
Chronic myeloid leukemia (CML) treatment with BCR-ABL inhibitors is often hampered by development of drug resistance. In a screen for novel chemotherapeutic drug candidates with genotoxic activity, we identified a bisindolylmaleimide derivative, IX, as a small molecule compound with therapeutic pote...
Autores principales: | Zhang, Xin, Jia, Deyong, Ao, Junping, Liu, Huijuan, Zang, Yi, Azam, Mohammad, Habib, Samy L., Li, Jia, Ruan, Xinsen, Jia, Hao, Wang, Xueying, Li, Baojie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342526/ https://www.ncbi.nlm.nih.gov/pubmed/27564101 http://dx.doi.org/10.18632/oncotarget.11566 |
Ejemplares similares
-
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells
por: Chai, Juin Hsien, et al.
Publicado: (2011) -
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022) -
IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015) -
BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020) -
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)